SCHEMBL21890432

SCHEMBL21890432

c1ccc(-n2c3cc4c(cc3c3c5sc6ccccc6c5ccc32)c2ccccc2n2ccnc42)cc1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21890526 0.93 FEN1 (0.32)
SCHEMBL21890807 0.91 PDE4A (0.31)
SCHEMBL21890604 0.87 KDM4E (0.33) KDM4EATML3MBTL1
SCHEMBL21890164 0.84 KDM4E (0.43) KDM4EATML3MBTL1
SCHEMBL21890409 0.83 KDM4E (0.39) KDM4EATML3MBTL1
SCHEMBL17299656 0.81 ATM (0.46) KDM4EATML3MBTL1
SCHEMBL21890163 0.80 KDM4E (0.30) KDM4EATML3MBTL1
SCHEMBL21890531 0.80 KDM4E (0.36) KDM4EATML3MBTL1
SCHEMBL21890255 0.80 KDM4E (0.38) KDM4EATML3MBTL1
SCHEMBL21890171 0.79 KDM4E (0.39) KDM4EATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230068759-A1 DONOR-ACCEPTOR TYPE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON IMIDAZO[1,2-F]PHENANTHRIDINE AND ANALOGUES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2023-03-02 US disclosed
US-20200227656-A1 DONOR-ACCEPTOR TYPE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON IMIDAZO[1,2-F]PHENANTHRIDINE AND ANALOGUES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2020-07-16 US disclosed
US-10615349-B2 Donor-acceptor type thermally activated delayed fluorescent materials based on imidazo[1,2-F]phenanthridine and analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2020-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200227656-A1 DONOR-ACCEPTOR TYPE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON IMIDAZO[1,2-F]PHENANTHRIDINE AND ANALOGUES SUN2, STAU1, HELZ KDM4E 4206/4885ATM 3709/4885L3MBTL1 1232/4885
US-20230068759-A1 DONOR-ACCEPTOR TYPE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON IMIDAZO[1,2-F]PHENANTHRIDINE AND ANALOGUES SUN2, STAU1, HELZ KDM4E 4206/4885ATM 3709/4885L3MBTL1 1232/4885
US-10615349-B2 Donor-acceptor type thermally activated delayed fluorescent materials based on imidazo[1,2-F]phenanthridine and analogues SUN2, STAU1, HELZ KDM4E 4206/4885ATM 3709/4885L3MBTL1 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.